Prof Noreen Starling

There are many other questions about what are the other combinations of this sort of drug, duraxone and racib, but indeed other drugs that are also rapidly coming through clinical trials.

For me, this is really the key that unlocks the transformative treatment potential for pancreatic cancer.

So it's going to be a really busy clinical trials landscape.

That is wonderful.

We've been looking for that in pancreatic cancer for such a long time.

I think it's a triumph for science and it's a triumph for patients.

There's two answers to that.

One is the length of time it takes in terms of the regulator to review the data in order to allow the drug to be available.

And within every jurisdiction, there will also need to be reimbursement considerations.

And for the UK, that will be a nice appraisal, which looks at benefit and resource and cost.

That timeline can vary.

You know, I would hope that we can see progress within this next year or certainly within the next couple of years.

But it's such an important breakthrough.

I would hope the system can move quickly in regard to this.

Absolutely.

So the two main other cancers where we can see RAS mutations include non-small cell lung cancer and colorectal cancer.

In fact, RAS mutations might be present in about 50 to 60% of tumours of patients with colorectal cancer.

So there's definitely efforts and trials coming focused on both of these diseases.

There may be additional challenges.

RAS is not the same in every disease.